The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Clinical and Pharmacogenetic Predictors of Circulating Atorvastatin and Rosuvastatin Concentrations in Routine Clinical Care
Open accessAbstract
Background—: A barrier to statin therapy is myopathy associated with elevated systemic drug exposure. Our objective was to examine the association between clinical and pharmacogenetic variables and statin concentrations in patients. Methods and Results—: In total, 299 patients taking atorvastatin or rosuvastatin were prospectively recruited at an outpatient referral center. The contribution of clinical variables and transporter gene polymorphisms to statin concentration was assessed using multiple linear regression. We observed 45-fold variation in statin concentration among patients taking the same dose. After adjustment for sex, age, body mass index, ethnicity, dose, and time from last dose, SLCO1B1 c.521T>C ( P <0.001) and ABCG2 c.421C>A ( P <0.01) were important to rosuvastatin concentration (adjusted R 2 =0.56 for the final model). Atorvastatin concentration was associated with SLCO1B1 c.388A>G ( P <0.01) and c.521T>C ( P <0.05) and 4β-hydroxycholesterol, a CYP3A activity marker (adjusted R 2 =0.47). A second cohort of 579 patients from primary and specialty care databases were retrospectively genotyped. In this cohort, genotypes associated with statin concentration were not differently distributed among dosing groups, implying providers had not yet optimized each patient’s risk–benefit ratio. Nearly 50% of patients in routine practice taking the highest doses were predicted to have statin concentrations greater than the 90th percentile. Conclusions—: Interindividual variability in statin exposure in patients is associated with uptake and efflux transporter polymorphisms. An algorithm incorporating genomic and clinical variables to avoid high atorvastatin and rosuvastatin levels is described; further study will determine whether this approach reduces incidence of statin myopathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While genetic testing in patients with statin myopathy has not yet become commonplace, there are some clear genetic signals, with variants of genes encoding drug transporters in both the liver and skeletal muscle that increase serum statin concentration linked to muscle side effects (see Supplementary material online, Table S5).106–109”
From Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management (2015) · cites this paper as [109]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2000) · doi:10.32614/r.manuals · Cited by 355,893
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Self-citationSLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043 · cited 2×
“Interestingly, the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) showed a link between this SNP and reduced risk for simvastatin-associated myopathy.(4) In our population, the SLCO1B1 c.”
BackgroundThompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
Bruckert, E., Hayem, G., Dejager, S., Yau, C., & Bégaud, B. (2005) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-005-5686-z · Cited by 1,226
Genest, J. J., McPherson, R., Frohlich, J. J., Anderson, T. J., Campbell, N. R. C., Carpentier, A. C., Couture, P., Dufour, R., Fodor, G. J., Francis, G. A., et al. (2009) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(09)70715-9 · Cited by 765
Self-citationInhibition of Intestinal Cholesterol Absorption by Ezetimibe in Humans
Sudhop, T., Lütjohann, D., Kodal, A., Igel, M., Tribble, D. L., Shah, S., Perevozskaya, I., & von Bergmann, K. (2002) · Circulation · doi:10.1161/01.cir.0000034044.95911.dc · Cited by 682
Niemi, M., Pasanen, M. K., & Neuvonen, P. J. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002857 · Cited by 639
Tirona, R. G., Leake, B. F., Merino, G., & Kim, R. B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103792200 · Cited by 625
Self-citationIntronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs
Wang, D., Guo, Y., Wrighton, S. A., Cooke, G., & Sadée, W. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.28 · Cited by 507
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–195 of 195
Role of Vitamin D Pathway Gene Polymorphisms on Rifampicin Plasma and Intracellular Pharmacokinetics
Allegra, S., Fatiguso, G., Calcagno, A., Baietto, L., Motta, I., Favata, F., Cusato, J., Bonora, S., Perri, G. D., & D’Avolio, A. (2017) · Pharmacogenomics · doi:10.2217/pgs-2017-0176 · Cited by 15
Soko, N. D., Chimusa, E. R., Masimirembwa, C. M., & Dandara, C. (2018) · The Pharmacogenomics Journal · doi:10.1038/s41397-018-0035-3 · Cited by 19
ATP-Binding Cassette Transporters in the Clinical Implementation of Pharmacogenetics
López-Fernández, L. A. (2018) · Journal of Personalized Medicine · doi:10.3390/jpm8040040 · Cited by 15
Maslub, M. G., Radwan, M. A., Daud, N. A. A., & Sha’aban, A. (2023) · European journal of medical research · doi:10.1186/s40001-023-01038-1 · Cited by 14
Gjestad, C., Hole, K., Haslemo, T., Diczfalusy, U., & Molden, E. (2019) · The AAPS Journal · doi:10.1208/s12248-019-0330-1 · Cited by 14
Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial
Murphy, W. A., Lin, N., Damask, A., Schwartz, G. G., Steg, P. G., Szarek, M. J., Banerjee, P., Fazio, S., Manvelian, G. Z., Pordy, R. C., et al. (2022) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.121.003503 · Cited by 16
Zhong, Z., Wu, H., Li, B., Li, C., Liu, Z., Yang, M., Zhang, Q., Zhong, W. H., & Zhao, P. (2018) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.22408 · Cited by 14
Walker, L. E., Yip, V. L. M., & Pirmohamed, M. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386882-4.00020-7 · Cited by 14
Statin intolerance: myths and facts
Laufs, U., & Isermann, B. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa582 · Cited by 14
Variant Discovery Using Next-Generation Sequencing and its Future Role in Pharmacogenetics
Russell, L. E., & Schwarz, U. I. (2020) · Pharmacogenomics · doi:10.2217/pgs-2019-0190 · Cited by 14
Self-citationKim, C. O., Oh, E. S., Kim, H., & Park, M. S. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s129586 · Cited by 13
Karadurmuş, L., Kurbanoğlu, S., Uslu, B., & Özkan, S. A. (2022) · Methods and Protocols · doi:10.3390/mps5060090 · Cited by 12
van Boheemen, L., Tett, S. E., Sohl, E., Hugtenburg, J. G., van Schoor, N. M., & Peeters, G. M. E. E. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0370-5 · Cited by 12
Organic Anion‐Transporting Polypeptides
Tirona, R. G., & Kim, R. B. (2014) · doi:10.1002/9781118705308.ch4 · Cited by 12
Self-citationStatins, Allies against Antibiotic Resistance?
Abavisani, M., Hoseinzadeh, M., Khayami, R., Kodori, M., Soleimanpour, S., & Sahebkar, A. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867331666230829141301 · Cited by 12
Lee, N., Maeda, K., Fukizawa, S., Ieiri, I., Tomaru, A., Akao, H., Takeda, K., Iwadare, M., Niwa, O., Masauji, T., et al. (2019) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2019.08.004 · Cited by 11
Characterization of ADME Gene Variation in Colombian Population by Exome Sequencing
Silgado-Guzmán, D. F., Angulo-Aguado, M., Morel, A., Niño-Orrego, M. J., Ruiz‐Torres, D. A., Bravo, N. C. C., Restrepo, C. M., Ortega‐Recalde, O., & Fonseca, D. J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.931531 · Cited by 11
Personalized Medicine in Lipid-Modifying Therapy
Tomlinson, B., Lin, C.-H., Chan, P., & Lam, C. W. K. (2021) · Personalized Medicine · doi:10.2217/pme-2020-0110 · Cited by 11
Somers, T., Siddiqi, S., Maas, R. G. C., Sluijter, J. P. G., Buikema, J. W., van den Broek, P. H. H., Meuwissen, T. J., Morshuis, W. J., Rüssel, F. G. M., & Schirris, T. J. J. (2024) · Basic Research in Cardiology · doi:10.1007/s00395-023-01025-x · Cited by 10
Soko, N. D., Muyambo, S., Dandara, M. T. L., Kampira, E., Blom, D. J., Jones, E. S. W., Rayner, B. L., Shamley, D. R., Sinxadi, P., & Dandara, C. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13081185 · Cited by 10
Cai, L., Bai, X., Lei, H., Wu, H., Liu, Y., Zhu, Q., Zhang, S., Liu, Y., Lin, Q.-X., Chen, J., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00427 · Cited by 11
Study, T. S. H. C., Courlet, P., Decosterd, L. A., Saldanha, S. A., Cavassini, M. L., Stader, F., Stoeckle, M. P., Buclin, T., Marzolini, C., Csajka, C., et al. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00876-0 · Cited by 10
Oda, A., Suzuki, Y., Sato, B., Sato, H., Tanaka, R., Ono, H., Ando, T., Shin, T., Mimata, H., Itoh, H., et al. (2022) · Journal of Separation Science · doi:10.1002/jssc.202100950 · Cited by 10
Silveira, A. M. R., Duarte, G. H. B., Fernandes, A. M. A. P., Garcia, P. H. D., Vieira, N. R., Antônio, M. A., & Carvalho, P. D. O. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.752960 · Cited by 9
Bain, K. T., McGain, D., Cicali, E. J., Knowlton, C. H., Michaud, V., & Turgeon, J. (2019) · Clinical Case Reports · doi:10.1002/ccr3.2604 · Cited by 9
Lindsay, C., Musgaard, M., Russell, A. J., & Sitsapesan, R. M. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15893 · Cited by 8
Cholesterol Management in Neurology: Time for Revised Strategies?
Andronie-Cioară, F. L., Jurcău, A., Jurcău, M. C., Nistor-Cseppento, C. D., & Simion, A. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12121981 · Cited by 9
Preclinical Assessment of Atorvastatin for Treatment of Endocardial Fibroelastosis
Diaz‐Gil, D., Gierlinger, G., Silva-Gomez, N., Rech, L., Ortiz-Urbina, J., Saraci, K., Koutsogiannaki, S., Wolf, C. M., Kozlik-Feldmann, R. G., Mair, R., et al. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.03.014 · Cited by 8
Pitavastatin treatment remodels the HDL subclass lipidome and proteome in hypertriglyceridemia
Chapman, M. J., Orsoni, A., Mellett, N. A., Nguyen, A., Robillard, P., Shaw, J. E., Giral, P., Thérond, P., Swertfeger, D. K., Davidson, W. S., et al. (2023) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100494 · Cited by 8
Stupica, D., Bajrović, F. F., Blagus, R., Cerar, T., Collinet‐Adler, S., Ružić‐Sabljić, E., & Velušček, M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0261194 · Cited by 8
Jiang, Z., Wu, Z., Liu, R., Du, Q., Fu, X., Li, M., Kuang, Y., Lin, S., Wu, J., Xie, W., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1102810 · Cited by 9
Brazilian Cohort and Genes Encoding for Drug-Metabolizing Enzymes and Drug Transporters
Kim, V., van der Wal, T., Nishi, M. Y., Montenegro, L. R., Carrilho, F. J., Hoshida, Y., & Ono, S. K. (2020) · Pharmacogenomics · doi:10.2217/pgs-2020-0013 · Cited by 8
Han, J., Jang, E. J., Yee, J., Song, T., Kim, D., Park, J., & Gwak, H. S. (2023) · Scientific Reports · doi:10.1038/s41598-023-43179-7 · Cited by 7
Wang, H., Chen, Y., Li, P., Chen, Y., Yu, D., Tan, Q., Liu, X., & Guo, Z. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1001 · Cited by 7
Klose, G., Beil, F. U., Dieplinger, H., von Eckardstein, A., Föger, B., Gouni‐Berthold, I., Köenig, W., Kostner, G. M., Landmesser, U., Laufs, U., et al. (2014) · Der Internist · doi:10.1007/s00108-014-3492-z · Cited by 7
Europe aspires to set the record straight on familial hypercholesterolaemia
Watts, G. F., Pang, J., & Santos, R. D. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.04.016 · Cited by 7
Gerontology Issues in Cardiology Practice
Ткачева, О. Н., Belenkov, Y. N., IuA, K., & Zyryanov, S. K. (2019) · Kardiologiia · doi:10.18087/cardio.2019.12.n876 · Cited by 6
Rosuvastatin Pharmacogenetics in African Populations
Soko, N. D., Masimirembwa, C. M., & Dandara, C. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0168 · Cited by 6
Li, W., Sparidans, R. W., Wang, Y., Martins, M. L. F., de Waart, D. R., van Tellingen, O., Song, J., Lebre, M. C., van Hoppe, S., Wagenaar, E., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116644 · Cited by 5
Statins and adhesion molecules: a review of a novel pleiotropic property of statins
Sadeghi, M., Dehnavi, S., Shahbaz, S. K., Koushki, K., Butler, A. E., Jamialahmadi, T., & Sahebkar, A. (2025) · Immunologic Research · doi:10.1007/s12026-025-09653-2 · Cited by 5
Liu, J., Zhang, B., Chen, M., & Zheng, B. (2021) · Medicine · doi:10.1097/md.0000000000026278 · Cited by 5
Sverre, E., Munkhaugen, J., Kristiansen, O., Weedon‐Fekjær, H., Peersen, K., Gjertsen, E., Gullestad, L. L., Bergan, S., Husebye, E., & Vethe, N. T. (2023) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1089 · Cited by 5
Current Consensus and Controversies in Guidelines for Lipid and Hypertension Management in Diabetes
Ganda, O. P., & Mitri, J. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0790-1 · Cited by 6
Beyond Statins: Who and When to Prescribe?
Ganda, O. P. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1087-0 · Cited by 5
Medication Exposure in Highly Adherent Psychiatry Patients
Sutherland, J. J., Daly, T. M., Jacobs, K., Khawam, E. A., Pozuelo, L., Morrison, R. D., Milne, S. B., Daniels, J. S., & Ryan, T. P. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00375 · Cited by 5
The in vitro evaluation of statins as antimicrobials for trauma-related chronic infectionPreprint
Trombetta, R. P., Lowak, K., Albach, A., Lopez, R., Romano, D. R., Sanchez, C., & Wenke, J. C. (2020) · doi:10.21203/rs.3.rs-15891/v1 · Cited by 5
Zhou, X., Cai, L., Lai, W., Bai, X., Liu, Y., Zhu, Q., He, G., Chen, J., Huang, M., Zhou, Z., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00675 · Cited by 4
L’intolérance musculaire aux statines
Boulanger‐Piette, A., Bergeron, J., Desgreniers, J., Côté-Levesque, M., Brassard, D., Joanisse, D. R., & Frenette, J. (2015) · médecine/sciences · doi:10.1051/medsci/20153112014 · Cited by 4
Xiao, M., Zhang, L., Zhong, Y., & Xiao, G. (2020) · SAGE Open Medical Case Reports · doi:10.1177/2050313x20919623 · Cited by 4
Farooq, T., Naeem, U., Siddique, A., Kausar, S., Waheed, A., & Mumal, S. (2025) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-025-01022-x · Cited by 3
Differential effects of OATP2B1 on statin accumulation and toxicity in a beta cell model
Kwon, J., Kim, M. S., Blagojevic, C., Mailloux, J., Medwid, S. J., Tirona, R. G., Wang, R., & Schwarz, U. I. (2023) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2023.2262568 · Cited by 3
Self-citationFarmacogenómica: Aplicaciones cardiovasculares
Quiñones, L. A., Angela Roco, A., & Carla Miranda, M. (2015) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2015.04.008 · Cited by 3
GENETIC POLYMORPHISM AND EFFICIENCY OF LIPID-LOWERING THERAPY
KABAKOVA, A., & GALYAVICH, A. (2016) · The Bulletin of Contemporary Clinical Medicine · doi:10.20969/vskm.2016.9(3).75-81 · Cited by 3
Pharmacogenomics of Lipid-Lowering Agents: the Impact on Efficacy and Safety
Shatnawi, A. A., Kamran, Z., & Al–Share, Q. Y. (2022) · Personalized Medicine · doi:10.2217/pme-2022-0041 · Cited by 3
Population Pharmacokinetics of Atorvastatin in High‐Altitude and Plain Patients with Hyperlipidemic
Li, Y., Huang, Q., Zeng, X., Wang, R., & Li, W. (2023) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2376 · Cited by 3
Mouse NTCP–Mediated Rosuvastatin Uptake In Vitro and in Slc10a1-Deficient Mice
Russell, L. E., DeGorter, M. K., Ho, R. H., Leake, B. F., Schmerk, C. L., Mansell, S. E., & Kim, R. B. (2021) · The AAPS Journal · doi:10.1208/s12248-020-00540-2 · Cited by 3
Self-citationCreatine Kinase as a Biomarker
Watanabe, L. M., Pinhel, M. A. D. S., Noronha, N. Y., & Nonino, C. B. (2022) · Biomarkers in disease · doi:10.1007/978-3-031-07389-2_55 · Cited by 3
Classification of reported statin intolerance
Preiss, D., & Sattar, N. A. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000149 · Cited by 3
Mokbel, K., Weedon, M. N., DANIELS, R., Moye, V., & Jackson, L. M. (2025) · British Journal of General Practice · doi:10.3399/bjgp.2024.0806 · Cited by 2
The pharmacogenetics of rosuvastatin and implications for treatment: a systematic review
González‐Iglesias, E., Novalbos, J., & Abad‐Santos, F. (2025) · Pharmacogenomics · doi:10.1080/14622416.2025.2547565 · Cited by 2
Validation of a novel direct method to determine reduced adherence to atorvastatin therapy
Pivoriunas, J., Vethe, N. T., Husebye, E., Fagerland, M. W., Bergan, S., Kristiansen, O., Munkhaugen, J., & Sverre, E. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae001 · Cited by 3
Álvarez, L. A., Ramos, J., & Calleja‐Hernández, M. Á. (2024) · Farmacia Hospitalaria · doi:10.1016/j.farma.2024.03.010 · Cited by 2
McColl, E. R., Vassileva, V., & Piquette‐Miller, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00054-2 · Cited by 2
Fankhouser, R. W., Murrell, D. E., Anane, Y. Y., Hurley, D. L., Mamudu, H. M., & Harirforoosh, S. (2022) · Drug Metabolism and Personalized Therapy · doi:10.1515/dmpt-2021-0135 · Cited by 2
Xia, B., Liu, X., Li, Y., Liu, Y., Sun, W., Chen, J., Li, L., Pang, J., Chen, S., & Cheng, H. (2023) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2023/v35i277440 · Cited by 2
Tomlinson, B., Hu, M., Zhang, Y., Liu, Z.-M., & Chan, P. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.02.047 · Cited by 2
Hu, C. B., Wang, R., Tirona, R. G., & Schwarz, U. I. (2026) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2026.100339 · Cited by 1
Self-citationEthnicity and Response to Drug Therapy
Al-Rasheed, M. M., & Dzimiri, N. (2016) · InTech eBooks · doi:10.5772/64819
Statin therapy: time for a precision medicine approach?
Mehdar, A., Hegele, R. A., Kim, R. B., & Gryn, S. E. (2017) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2017.1356685 · Cited by 1
Self-citationSLCO1B1 and ABCG2 genotype‐informed phenotypes are related to variation in ramipril exposure
Abbes, H., Zubiaur, P., Soria‐Chacartegui, P., de la Torre, T., Villapalos‐García, G., Candau, C., Rodríguez‐Lopez, A., González‐Iglesias, E., Aldama, M., Navares‐Gómez, M., et al. (2024) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.14046 · Cited by 1
Pharmacokinetic Drug–Drug Interaction between Cilostazol and Rosuvastatin in Healthy Participants
Kim, D. H., Hong, J. H., Jung, W., Nam, K., Roh, J. S., Lee, H. J., Moon, J., Kim, K. Y., Jung, J. G., & Sunwoo, J. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00686-w · Cited by 1
Pharmacogenetics and the Practice of Medicine
Kathale, S. N., Dhawle, T., & Sanap, G. (2025) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-22957 · Cited by 1
ORGANIC ANION TRANSPORTING POLYPEPTIDES OATP
Tirona, R. G., & Kim, R. B. (2022) · Wiley eBooks · doi:10.1002/9781119739883.ch5 · Cited by 1
Self-citationPersonalized Medicine: Importance of Clinical Interpretative Skills for Real-World Patient Care
Gryn, S. E., & Kim, R. B. (2014) · Personalized Medicine · doi:10.2217/pme.14.16
Self-citationYin, Z. P. (2014) · Scholarship@Western (Western University)
Prediction of response to lipid-lowering treatments
Tomlinson, B., Chan, P., & Liu, Z. (2018) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2018.1526080
Stellenwert der lipidsenkenden Therapie in der Sekundärprophylaxe bei KHK
Hinck, A., & Sechtem, U. P. (2018) · Der Klinikarzt · doi:10.1055/a-0792-1177
Pharmacoepigenetics of Statins
Zambrano, T., Saavedra, K., & Salazar, L. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813939-4.00031-0
Genetic Risk Factors for Statin-Associated Muscle Symptoms (SAMS)
Rosario-Berrios, A. N., Duconge-Soler, J., & Ruaño, G. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-33304-1_11
Pharmacogenomics in Cardiovascular Diseases
Xiang, X., & Jin, Z. (2020) · Springer eBooks · doi:10.1007/978-981-15-3895-7_2
Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment
Alamer, A., Te, C., & Fazel, M. T. (2021) · Annals of Internal Medicine · doi:10.7326/l20-1454
Pharmacogenetics to Avoid Adverse Drug Reactions
López-Fernández, L. A. (2022) · MDPI eBooks · doi:10.3390/books978-3-0365-3343-8
Creatine Kinase as a Biomarker
Watanabe, L. M., Pinhel, M. A. D. S., Noronha, N. Y., & Nonino, C. B. (2022) · Biomarkers in disease · doi:10.1007/978-3-030-81304-8_55-1
Витковский, Ф. А., Даниленко, Н. Г., Sa, L., Сидорович, Э. К., & Пархач, Л. П. (2023) · Неврология и нейрохирургия Восточная Европа · doi:10.34883/pi.2023.13.4.040
Drum, C. L., Goh, E., Wu, L. H., Pakkiri, L. S., Ng, M., George, M., Liu, J., Aminkeng, F., Tai, E. S., & Tan, J. W. C. (2024) · Research Square · doi:10.21203/rs.3.rs-4023614/v1
Naushad, S. M., Palanichamy, P. K., Sreemanthula, J. B., Devi, Y. R. K. D., Gopi, P., Hussain, T., & Kutala, V. K. (2025) · Pharmacological Reports · doi:10.1007/s43440-025-00746-1
Afzal, M., Adeeb, N. B., Musa, N. F., Noor, D. A. M., & Daud, N. A. A. (2025) · Saudi Medical Journal · doi:10.15537/smj.2025.46.8.20250310
Abdel-Latif, R., Mohammed, S., Saad, M., Kunji, K. B., Al‐Muftah, W., El-Menyar, A. A., & Suwaidi, J. M. S. A. (2026) · Pharmaceuticals · doi:10.3390/ph19030514
Rhabdomyolysis resulting from the interaction of rosuvastatin and abiraterone: A case study
Blagojevic, C., Kim, R. B., Juurlink, D. N., & Zipursky, J. S. (2026) · Seminars in Oncology · doi:10.1016/j.seminoncol.2026.152559
Self-citationDove, E., Peter, S., Lusk, H. J., & Lynch, K. L. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.09.025
Sánchez-Redondo, A., Thomas, L., Arias-Aragón, F., Ramiro-Lozano, J. M., Gamero-de-Luna, E. J., Mata-Martín, C., & LLerena, A. (2026) · Pharmaceuticals · doi:10.3390/ph19111701
Klose, G., Beil, F. U., Dieplinger, H., von Eckardstein, A., Föger, B., Gouni‐Berthold, I., Heigl, F., Köenig, W., Kostner, G. M., Landmesser, U., et al. (2014) · Der Internist · doi:10.1007/s00108-014-3576-9
Metadata
- Authors
- DeGorter, M. K., Tirona, R. G., Schwarz, U. I., Choi, Y.-H., Dresser, G. K., Suskin, N., Myers, K., Zou, G., Iwuchukwu, O., Wei, W.-Q., Wilke, R. A., Hegele, R. A., & Kim, R. B.
- Affiliations
- Western University (CA)
- ORCID
- Venue
- Circulation: Cardiovascular Genetics
- Published
- 2013-08
- Volume
- 6
- Issue
- 4
- Pages
- 400-408
- ISSN
- 1942-325X (ISSN-L)
- 1942-3268
- PMC
- PMC3922121
- OpenAlex
- W2164884234
- Cited by
- 195
- References
- 50
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 8 · 2023: 17 · 2022: 15 · 2021: 17 · 2020: 23 · 2019: 16 · 2018: 20 · 2017: 11 · 2016: 21 · 2015: 11 · 2014: 16 · 2013: 4
- FWCI
- 18.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Circulation Cardiovascular Genetics (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Scholarship@Western (Western University) (submittedVersion)
- Funders
- Canadian Institutes of Health Research (MOP-89753)
- National Institute of General Medical Sciences (T32GM007569)
- National Center for Research Resources (UL1RR024975)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- atorvastatin, rosuvastatin, statin-induced myopathy, pharmacogenetics, SLCO1B1, ABCG2, drug transporter polymorphisms, interindividual variability, 4β-hydroxycholesterol, CYP3A activity, statin dosing, statin safety
- MeSH terms
- Rosuvastatin Calcium, Atorvastatin, ATP Binding Cassette Transporter, Subfamily G, Member 2, Adult, Aged, Aged, 80 and over, Alleles, Cholesterol, Female, Fluorobenzenes, Genotype, Heptanoic Acids, Humans, Hydroxycholesterols, Hypercholesterolemia, Male, Middle Aged, Neoplasm Proteins, Polymorphism, Genetic, Prospective Studies, Pyrimidines, Pyrroles, Retrospective Studies, Sulfonamides, Cohort Studies, Linear Models, Databases, Factual, ATP-Binding Cassette Transporters, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Polymorphism, Single Nucleotide, Organic Anion Transporters, Liver-Specific Organic Anion Transporter 1, Cytochrome P-450 CYP3A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
